← Back to Pipeline Dashboard Open Source Medicine Foundation

mRNA-1083 (Moderna Combined Influenza + COVID-19 mRNA Vaccine)

Regulatory Submission Filed

Developer: Moderna  |  Target Disease: Seasonal influenza + COVID-19 (combination)

Category Resource

Explore licensed vaccines, adverse event reporting data, and history for this disease.

View Seasonal influenza + COVID-19 (combination) Vaccine Guide →
  1. Phase 1
  2. Phase 2
  3. Phase 3
  4. Filed
  5. Approved
Development Phase Regulatory Submission Filed Primary Status
Platform Technology mRNA Biologic Architecture
Target Indication Seasonal influenza + COVID-19 (combination) Pathogen / Antigen
Last Verified 2026-08-01 Tier 1 Multi-Source Checked

Multi-Jurisdiction Regulatory Status

Official licensing, rolling submissions, or authorization status tracked across major health authorities.

Regulatory Authority Status & Details
US FDA Under Regulatory Review Date: 2024-10-15BLA submitted to FDA following positive Phase 3 immunogenicity data vs separate flu & COVID vaccines
EMA (Europe) Under Regulatory Review Date: 2024-11-01EMA regulatory submission planned/under review
Health Canada Not Filed / Pre-submission Date: 2025-02-01Filing anticipated
TGA (Australia) Not Filed / Pre-submission Date: 2025-03-01Filing anticipated

Progress and adoption outlook

Where this candidate sits on a fixed development ladder, and when a licence and a routine-use recommendation could follow in each jurisdiction, as scenario bands. Input grade: Regulator-confirmed status date in at least one jurisdiction.

75% of the ladderA · regulator-dated
  1. Preclinical
  2. Phase 1
  3. Phase 1/2
  4. Phase 2
  5. Phase 2/3
  6. Phase 3
  7. Submitted to a regulator
  8. Under regulatory review
  9. Approved / authorised
  10. Recommended for routine use

Current position: Submitted to a regulator

Status and projected windows by jurisdiction
JurisdictionStatus in the recordSubmissionRegulator decisionEarliest routine use
United StatesFDA (CBER) · ACIP (CDC)under review (2024-10-15, regulator confirmed)2024-102024-10 to 2024-102027-012026-11 to 2027-072027-042026-11 to 2028-03
European UnionEMA (CHMP) and European Commission · national bodies (STIKO, HAS, Folkhälsomyndigheten and others)under review (2024-11-01, company estimate)2024-112024-11 to 2024-112027-012026-11 to 2027-072027-072026-12 to 2029-01
CanadaHealth Canada · NACInot filed (2025-02-01, company estimate)2026-102026-10 to 2026-102027-082027-04 to 2028-012027-122027-05 to 2029-01
United KingdomMHRA · JCVIno jurisdiction-specific filing knownThe MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used.
AustraliaTGA · ATAGInot filed (2025-03-01, company estimate)TGA registration-timeframe pages timed out on 2026-10-24; no target is used.
JapanPMDA / MHLW · MHLW immunisation subcommitteeno jurisdiction-specific filing knownPMDA English pages reached on 2026-10-24 state that target review times exist but give no figure.
WHO prequalificationWHO Prequalification · SAGEno jurisdiction-specific filing knownWHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used.

Each window shows the typical scenario with the fast-to-slow band beneath it (year-month). Bands come from the parameters on the outlook model page; they are not forecasts.

Scientific Profile & Documentation

Platform Architecture
mRNA
Lead Developer
Moderna
Next Expected Milestone
FDA target PDUFA action date and ACIP review for 2025-2026 respiratory season
Analyst & Development Notes
Illustrates multi-jurisdiction status: filed/under review in some regions while US pathway was withdrawn pending refiling.
Primary Source Documentation
Moderna Analyst Day / pipeline disclosures →

Registered Clinical Trials & Studies

Direct registry links to active, completed, or pivotal registration studies across phases.

No primary ClinicalTrials.gov record linked directly. Study data tracked via regulatory submission filings and peer-reviewed releases.

Milestone Overview

  • Stage Verification
    Regulatory Submission Filed confirmed as of 2026-08-01.
  • Target Milestone
    FDA target PDUFA action date and ACIP review for 2025-2026 respiratory season

Vaccine Data Navigator Candidate Profile Registry:

This candidate profile is indexed across all clinical development levels (Preclinical through Phase 1–3, Regulatory Filing, and Licensure) from primary registry databases (ClinicalTrials.gov, WHO ICTRP, FDA CBER, EMA, Health Canada, TGA Australia). Data are updated continuously to track global biologic and vaccine pipelines.